In the present work using preclinical models of RA, additive effects were evident when suboptimal doses of BMS-986142 were co-administered with either etanercept, a TNF-α inhibitor, or the murine form of abatacept (CTLA-4-Ig), a T-cell co-stimulation blocker. This evidence concerns the gene TNF and rheumatoid arthritis.